(Press-News.org) Highlights:
An FDA-approved vaccine for smallpox and mpox is effective but causes side effects. The other requires multiple doses.
An experimental single-dose vaccine uses the horsepox virus to harness the benefits of both strategies.
Previous studies suggest that inoculation with horsepox elicits an antibody response to mpox and provides 100% protection in animal models.
New data show that the horsepox virus is significantly more attenuated, or weakened, compared to the virus used in the FDA-approved live virus vaccine.
Washington, D.C.—Vaccines that prevent smallpox and mpox come in 2 varieties. One uses a single shot of a live virus but carries risk of serious side effects; the other, which is newer and made with replication deficient virus, has fewer side effects but requires 2 doses. An experimental vaccine under development at Tonix Pharmaceuticals in Frederick, Md., aims to combine the benefits of both vaccine strategies. It uses the horsepox virus as a protective agent to confer the safety of a multi-dose vaccine in a single shot.
This week in mSphere, scientists at Tonix Pharmaceuticals report on studies suggesting that the horsepox virus in the experimental vaccine is substantially more attenuated—and thus less likely to trigger a systemic infection—than the vaccinia virus used in the single-dose vaccine already approved by the U.S. Food and Drug Administration (FDA).
“We are trying to go for the immunity of the old vaccines and safety profile of the new ones, and so far the data are very promising,” said virologist Farooq Nasar, Ph.D, senior author on the study. “We would like to be in the middle.”
Smallpox, which is caused by the variola virus, was a highly contagious disease with a fatality rate between 30% and 97%. Historical records suggest it began infecting people thousands of years ago, and the World Health Organization (WHO) estimated that smallpox killed between 300-500 million people in the 20th century. An effective vaccination campaign that began in the 1950s stopped the spread, and in 1980 the WHO declared the disease eradicated.
Mpox, formerly known as monkeypox, is a related disease caused by the monkeypox virus, which like variola is a member of the genus Orthopoxvirus. Multiple mpox outbreaks have occurred since 2022 and estimates of case fatality rate vary from 0.2% to 11%. The 2 FDA-approved vaccines for smallpox are also approved for use to prevent mpox infection.
The approved live-virus smallpox vaccine includes the vaccinia virus, a less harmful member of the Orthopoxvirus family that helps the body develop defenses against smallpox infection. A few years ago, however, researchers discovered that smallpox vaccines used before and during the American Civil War contained a virus more than 99% genetically similar to horsepox—another Orthopoxvirus. That discovery launched investigations into whether a vaccine with live, attenuated horsepox could confer immunity without the unwelcome side effects of the live vaccinia virus-based vaccine.
Previous studies by researchers at Tonix Pharmaceuticals and elsewhere have reported that the experimental vaccine provoked an antibody response but did not cause disease in non-human primates; in addition, the vaccine protected non-human primates against a lethal exposure to the monkeypox virus with no occurrence of clinical disease.
The new study, led by virologists Nasar and Stefanie Trefry, Ph.D., builds on those findings. Testing in both human cell lines and mouse models, the researchers compared virus replication in models with vaccinia virus strains to those given the experimental horsepox virus.
They found that the horsepox virus is attenuated up to 1,000-fold more than the vaccinia virus strains, which means it contained a much lower concentration of infectious particles. Attenuation weakens a virus, which means it is less likely to trigger a systemic infection in the host. Mice given the vaccinia-based vaccine strains often developed severe symptoms, while mice given the experimental horsepox vaccine showed no adverse effects.
The researchers are now planning phase I human clinical trials to test the safety of the vaccine in people. Smallpox now only exists in laboratories in the United States and Russia, and researchers continue to investigate smallpox vaccines as a defense against smallpox as a bioterror agent. The more urgent public health concern right now, said Nasar, is preventing future mpox outbreaks. The new vaccine hopes to serve both purposes.
“We’re focused on making a product that can be used against both mpox and smallpox,” he said.
###
The American Society for Microbiology is one of the largest professional societies dedicated to the life sciences and is composed of over 32,000 scientists and health practitioners. ASM's mission is to promote and advance the microbial sciences.
ASM advances the microbial sciences through conferences, publications, certifications, educational opportunities and advocacy efforts. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to diverse audiences.
END
Potential single-dose smallpox and mpox vaccine moves forward
2024-11-13
ELSE PRESS RELEASES FROM THIS DATE:
Mass General Brigham Gene and Cell Therapy Institute names Spark Grant recipients
2024-11-13
The Mass General Brigham Gene and Cell Therapy Institute, a hub of innovation dedicated to accelerating groundbreaking research, conducting clinical trials and developing FDA-approved treatments, today announced four winning project groups, consisting of seven individuals, of its second annual Spark Grant program. The program was created to fund gene and cell therapy projects by Mass General Brigham investigators that demonstrate tangible advancements towards clinical applications and commercialization outcomes, including licensing, partnerships, or new company creation. A total of $1,150,000 ...
New discovery may lead to more effective treatment for cardiovascular disease
2024-11-13
CLEVELAND—Researchers at Case Western Reserve University have identified a new target to treat atherosclerosis, a condition where plaque clogs arteries and causes major cardiac issues, including stroke and heart attack.
In a new study, published in the journal Cell Reports, they identified an inflammation-reducing molecule—called itaconate (ITA)—that could be the foundation of a new approach to treat such a common and deadly disease.
Heart disease is the leading cause of death for ...
Developing advanced recycling technology to restore spent battery cathode materials
2024-11-13
A research team led by Dr. Jung-Je Woo at the Gwangju Clean Energy Research Center of the Korea Institute of Energy Research (KIER) has successfully developed a cost-effective and eco-friendly technology for recycling cathode materials* from spent lithium-ion batteries.
*Cathode Materials: Materials that play a crucial role in generating electricity by storing and releasing lithium ions during battery charging and discharging.
With the recent rise in electric vehicles and mobile devices, managing spent batteries has become a critical global challenge. By 2040, the number of decommissioned electric vehicles is expected to exceed 40 million*, leading ...
An advance toward inhalable mRNA medications, vaccines
2024-11-13
Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A study in the Journal of the American Chemical Society reports steps toward making inhalable mRNA medicines a possibility. Researchers outline their improved lipid-polymer nanoparticle for holding mRNA that is stable when nebulized and successfully delivers aerosols (liquid droplets) in mice’s lungs.
mRNA ...
A step toward safer X-rays with new detector technology
2024-11-13
X-rays are a common component of diagnostic testing and industrial monitoring, used for everything from monitoring your teeth to scanning your suitcase at the airport. But the high-energy rays also produce ionizing radiation, which can be dangerous after prolonged or excessive exposures. Now, researchers publishing in ACS Central Science have taken a step toward safer X-rays by creating a highly sensitive and foldable detector that produces good quality images with smaller dosages of the rays.
“This advancement reduces detection limits and paves the way for safer and more energy-efficient medical imaging and industrial monitoring,” says Omar F. Mohammed, ...
On the origin of life: How the first cell membranes came to exist
2024-11-13
Few questions have captivated humankind more than the origin of life on Earth. How did the first living cells come to exist? How did these early protocells develop the structural membranes necessary for cells to thrive and assemble into complex organisms?
New research from the lab of University of California San Diego Professor of Chemistry and Biochemistry Neal Devaraj has uncovered a plausible explanation involving the reaction between two simple molecules. This work appears in Nature Chemistry.
Life on Earth ...
New evidence-based information from NCCN offers tangible and moral support for people trying to quit smoking
2024-11-13
PLYMOUTH MEETING, PA [November 13, 2024] — The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—today announced the publication of a new patient guideline designed to provide critical support and guidance for individuals with cancer who are seeking to quit smoking. Continued smoking elevates the risk of developing additional cancers, reduces the effectiveness of treatment, exacerbates treatment side effects, and is associated with shorter survival. The new NCCN Guidelines for Patients®: Quitting Smoking explains how to best use the tools that exist to help anyone quit ...
Solving complex problems faster: Innovations in Ising machine technology
2024-11-13
Computers are essential for solving complex problems in fields, like scheduling, logistics, and route planning, but traditional computers struggle with large-scale combinatorial optimization, as they can’t efficiently process vast numbers of possibilities. To address this, researchers have explored specialized systems.
One such system is the Hopfield network, a significant artificial intelligence breakthrough from 1982, proven in 1985 to solve combinatorial optimization by representing solutions as energy levels and naturally finding the lowest energy, or optimal, solution. ...
Grief-specific cognitive behavioral therapy vs present-centered therapy
2024-11-13
About The Study: This randomized clinical trial demonstrates that cognitive behavioral therapy for prolonged grief was superior to present-centered therapy after treatment and at follow-up with regard to comorbid symptoms. Both treatments were shown to be effective and acceptable, showing the potential for dissemination and increasing patient choice.
Corresponding Author: To contact the corresponding author, Rita Rosner, PhD, email rita.rosner@ku.de.
To access the embargoed study: Visit our For The Media website ...
New species discovered with refined DNA technology
2024-11-13
Sometimes plants are so similar to each other that the methods developed by 18th century scientist Carl Linnaeus for identifying species are not enough. In a thesis from the University of Gothenburg, completely new species of daisies have been discovered when analysed using modern DNA technology.
There are currently estimated to be around 8.7 million different species on Earth, of which around 2.2 million are found in the oceans. Many species can be identified in the classical way, by their physical characteristics, the morphology. For over a decade, botanists and zoologists have also been using DNA sequencing to more accurately identify species. ...